• Novartis will present 48 abstracts from its leading MS portfolio, including new data on recently FDA-approved Kesimpta® (ofatumumab)the first and only self-administered, targeted B-cell therapy for relapsing forms of MS (RMS)—Mayzent® (siponimod) and Gilenya® (fingolimod)
     
  • New pivotal data from ASCLEPIOS trials evaluating the efficacy and safety of Kesimpta in a subgroup of treatment-naïve RMS patients will be presented for the first time1